Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
N/A
1(20.0%)
5Total
Phase 2(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03473158Not ApplicableCompleted

Fetal Reduction: Mechanical vs Chemical

Role: collaborator

NCT04411212Phase 2Unknown

G-CSF and PRP in Patients With Recurrent Implantation Failure

Role: lead

NCT04407052Phase 2Unknown

Double Trigger in Patients With Low Proportion of Mature Oocytes

Role: lead

NCT04407065Phase 2Unknown

Double Trigger in Patients With Low Number of Oocytes Retrieved Per Number of Preovulatory Follicles

Role: lead

NCT03373149Phase 2Unknown

Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response

Role: lead

All 5 trials loaded